Logo of Eve Health (ASX:EVE)Latest Eve Health (ASX:EVE) News

Page 2
Page 2 of 4

Healthcare Wrap - Week 11 (9 Mar -> 13 Mar) 2026

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.
Logan Eniac
14 Mar 2026

EVE Health Group Secures $0.9M to Boost Drug Reformulation Pipeline

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.
Ada Torres
13 Mar 2026

EVE Unveils $30B Pipeline of Reformulated Sexual Health and Cardiovascular Drugs

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.
Ada Torres
10 Mar 2026

Healthcare Wrap - Week 7 (9 Feb -> 13 Feb) 2026

Healthcare stocks split into two stories this week: big names sold off hard, while a few small caps ran on clear news. The biggest moves came from a sharp fall in Pro Medicus and Cochlear, while Noxopharm jumped after a top-tier journal publication.
Logan Eniac
14 Feb 2026

EVE Health Group Launches Libbo™ and Digital Men’s Health Platform in Australia

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.
Ada Torres
10 Feb 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
31 Jan 2026

EVE Health Hits Key Milestones with Dyspro™ Prescriptions and Libbo™ Manufacturing

EVE Health Group has transitioned from development to commercial rollout, delivering first patient prescriptions of Dyspro™ and completing initial manufacturing of Libbo™, supported by a $1.1 million capital raise.
Ada Torres
30 Jan 2026

EVE Advances Men’s Health with Libbo™ Ready for Market Launch

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.
Ada Torres
30 Jan 2026

EVE Health Launches Nationwide Telehealth Support for Dyspro and Libbo Patients

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its women’s and men’s health products Dyspro™ and Libbo™.
Ada Torres
19 Nov 2025

EVE Launches Nationwide Telehealth Support for Dyspro and Libbo Patients

EVE Health Group has partnered with telehealth provider hubMed to deliver a national patient support program, enhancing care continuity for users of its Dyspro and Libbo therapies.
Ada Torres
19 Nov 2025

EVE Health Launches Dyspro™ and Libbo™ with $1.1M Boost for Commercial Rollout

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.
Ada Torres
31 Oct 2025

EVE Health Group Raises $1.1M to Accelerate Launch of Dyspro and Libbo

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.
Ada Torres
15 Oct 2025